

Eli Lilly Jumps, EchoStar Soars, UnitedHealth Drops
Aug 26, 2025
Eli Lilly's shares soared after their obesity drug trial showed promising results, helping patients shed significant weight. EchoStar experienced a remarkable stock jump following a pivotal $23 billion deal with AT&T, aimed at avoiding bankruptcy and enhancing network capabilities. Meanwhile, UnitedHealth faced scrutiny from the Justice Department, causing its stock to drop, despite some positive market interest. The contrasting fortunes create a thrilling snapshot of the current market landscape.
AI Snips
Chapters
Transcript
Episode notes
EchoStar's Spectrum Deal Changes The Game
- EchoStar struck a $23 billion deal to sell spectrum licenses to AT&T, materially improving its bankruptcy outlook and regulatory position.
- The transaction could spark additional bids from Starlink, T-Mobile, or others, adding upside and uncertainty.
Deal Timetable And Political Backing Matter
- The EchoStar deal is expected to close by mid-2026 and follows private briefings to the White House and FCC.
- National wireless leadership motivated high-level interest and could ease regulatory approval concerns.
Equity Rally Triggers Bond Repricing
- EchoStar's stock move also impacted its bonds, with certain Dish DBS bonds jumping significantly in the junk market.
- Equity gains often coincide with cross-asset shifts that reflect changing credit risk perceptions.